About Careers MedBlog Contact us

New Oral Drug Holds Promise for Aggressive Lymphoma Treatment

by Thilaka Ravi on May 27, 2010 at 3:20 PM
Font : A-A+

New Oral Drug Holds Promise for Aggressive Lymphoma Treatment

A new oral drug called lenalidomide promises positive results in patients with transformed lymphoma with few side effects, according to a new study.

45 per cent patients responded positively when treated with immunomodulatory medication, which kills lymphoma cells by activating the body's natural killer cells and by interrupting cancer cell signaling that leads to cell death.


21 percent showed complete remission, some for more than a year.

"The study results show a remarkable response rate for transformed lymphoma patients who have a very poor prognosis," says Craig Reeder, M.D. (http://www.mayoclinic.org/bio/10010343.html), Mayo Clinic hematologist (http://www.mayoclinic.org/hematology-oncology-sct/) and principal investigator for the phase II study at Mayo Clinic's Arizona (http://www.mayoclinic.org/arizona/) campus.

Although majority of patients responded well to the drug, results varied by the particular type of transformed lymphoma.

Dr. Reeder notes that while the number of patients treated with lenalidomide was small, the results are promising because of the response rate, the length of the response, and the simplicity of treatment. In patients who responded, the positive effect of lenalidomide was seen for a median of nearly 13 months.

Compared to chemotherapy drugs, lenalidomide is easy to administer and is well tolerated. "Its appeal is that it's not toxic to the patient," he says. Side effects were considered mild and included low white blood cell counts.

Further studies are needed to confirm its role in treating patients with transformed lymphoma.

The international study, involving 24 medical centers in the United States and Europe, will be presented at the American Society of Clinical Oncology (http://www.asco.org/) annual meeting June 4-8, 2010, in Chicago.

Source: ANI


Recommended Reading

Latest Drug News

Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
Myeloma Drug: New Findings
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Lower Dose of Acetaminophen Linked to Reduced Serious Liver Injury
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen
Tool to Identify Existing Drugs to Use in a Future Outbreak Developed
The new tool developed simulates tissue-specific infection of host cells of SARS-CoV-2 and then performs experiments to identify drugs for repurposing.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Oral Drug Holds Promise for Aggressive Lymphoma Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests